Hostname: page-component-5447f9dfdb-lr6j9 Total loading time: 0 Render date: 2025-07-29T00:46:26.345Z Has data issue: false hasContentIssue false
  • English
  • Français

Optimising neuroleptic treatment for psychotic illness

Published online by Cambridge University Press:  02 January 2018

Geoffrey Searle
Geoffrey Searle*
Affiliation:
Dorset Healthcare NHS Trust King's Park Unit, Gloucester Road, Boscombe, Bournemouth, BH7 6JE
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The release of the antipsychotic agents risperidone, sertindole and olanzepine forces difficult choices upon clinicians. The new compounds are better tolerated than neuroleptics, expensive and their long-term side-effects unknown. These choices can be made easier by the dose and side-effect minimisation procedure set out below, which aims to produce the greatest benefit and least harm from conventional neuroleptics.

Information

Type
Original Papers
Information
Psychiatric Bulletin , Volume 22 , Issue 9 , September 1998 , pp. 548 - 551
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists

References

Farde, L., Nordstrom, A.-L., Wiesel, F.-A., et al (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychitry, 49, 538–544.CrossRefGoogle ScholarPubMed
Hilton, T., Taylor, D. & Abel, K. (1996) Which dose of haloperidol? Psychiatric Bulletin, 20, 359–362.Google Scholar
McEvoy, J. P., Stiller, R. L. & Farr, R. (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. Journal of Clinical Pharmacology, 6, 133–138.Google ScholarPubMed
McEvoy, J. P., Hogarty, G. E. & Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48, 739–745.Google Scholar
Pickar, D., Labarca, R., Doran, A. R., et al (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry, 43, 669–676.Google Scholar
Thompson, C. (1994) The use of high-dose antipsychotic medication. Consensus statement. British Journal of Psychiatry, 164, 448–458.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.